
FDA approves new GENE THERAPY for rare skin disease
On April 29, the U.S. Food and Drug Administration authorized Zevaskyn, a first-of-its-kind gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), a devastating genetic condition causing fragile, blistering skin. Developed by Abeona …